EPKINLY Drug Insight and Market Forecast - 2032

This “EPKINLY Drug Insight and Market Forecast – 2032” report provides comprehensive insights about EPKINLY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the EPKINLY for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 –2032 is provided in this report along with a detailed description of the EPKINLY for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the EPKINLY market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary

EPKINLY (also known as Epcoritamab, GEN3013) is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology. Genmab's DuoBody-CD3 technology directs cytotoxic T cells selectively to elicit an immune response toward target cell types. Epcoritamab is designed to bind to CD3 on T cells and CD20 on B cells and induce T-cell mediated killing of CD20+ cells.

Epcoritamab is being codeveloped by AbbVie and Genmab as part of the companies' oncology collaboration. The companies will share commercial responsibilities in the US and Japan, with AbbVie responsible for further global commercialization. The companies are committed to evaluating epcoritamab as a monotherapy, and in combination, across lines of therapy in a range of hematologic malignancies. This includes an ongoing Phase III, open-label, randomized clinical trial evaluating epcoritamab as a monotherapy in patients with R/R DLBCL and a Phase III, open-label clinical trial evaluating epcoritamab in combination in patients with R/R FL.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the EPKINLY description, mechanism of action, dosage and administration, research and development activities in Diffuse Large B-cell lymphoma (DLBCL).
• Elaborated details on EPKINLY regulatory milestones and other development activities have been provided in this report.
• The report also highlights the EPKINLY research and development activities in DLBCL across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around EPKINLY.
• The report contains forecasted sales of EPKINLY for DLBCL till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DLBCL.
• The report also features the SWOT analysis with analyst views for EPKINLY in DLBCL.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publishing team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

EPKINLY Analytical Perspective

In-depth EPKINLY Market Assessment

This report provides a detailed market assessment of EPKINLY for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

EPKINLY Clinical Assessment

The report provides the clinical trials information of EPKINLY for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence EPKINLY dominance.
• Other emerging products for DLBCL are expected to give tough market competition to EPKINLY and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of EPKINLY in DLBCL.
• Our in-depth analysis of the forecasted sales data of EPKINLY from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the EPKINLY in DLBCL.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of EPKINLY?
• What is the clinical trial status of the study related to EPKINLY in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the EPKINLY development?
• What are the key designations that have been granted to EPKINLY for DLBCL?
• What is the forecasted market scenario of EPKINLY for DLBCL?
• What are the forecasted sales of EPKINLY in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to EPKINLY for DLBCL?
• Which are the late-stage emerging therapies under development for the treatment of DLBCL?

This product will be delivered within 2 business days.